跳至主要内容
临床试验/CTRI/2022/10/046178
CTRI/2022/10/046178尚未招募4 期

A Multi-centric, Non-Randomized, Open label, Non-Comparative, Active post marketing surveillance to evaluate the Safety and Efficacy of Wikoryl DS oral suspension in children suffering from common cold associated with fever

Alembic Pharmaceuticals Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1. Age: 2-12 years of age. (12-40 Kg body weight)
  • 2. Genders Eligible for Study: both Males and Females
  • 3. Patients with clinical diagnosis of common cold associated with fever. These symptoms may include rhinorrhea, nasal congestion, sneezing etc.
  • 4. Patients whose guardians can adhere to the protocol

排除标准

  • 1. Patients known to be hypersensitive to investigational product
  • 2. Patients with severe hepatic or renal dysfunction

研究者

相似试验